Draft:Martin Uram

iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients

Retrieved on: 
Thursday, July 15, 2021
Medicine, Eye surgery, Clinical medicine, Medical specialties, Glaucoma, Cataract surgery, Implant, Minimally invasive glaucoma surgery, Draft:Martin Uram

This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.

Key Points: 
  • This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.
  • Patients will also be followed to evaluate long-term benefits and tolerability of MINIjectTM in the treatment of mild to moderate glaucoma.
  • Michel Vanbrabant, CEO of iSTAR Medical, commented "We are very pleased that the FDA has granted us approval to bring this innovative technology to North American patients suffering from primary open angle glaucoma in the STAR-V trial.
  • iSTAR Medical SA is a private med-tech company developing minimally invasive ophthalmic implants for the treatment of glaucoma patients.

iSTAR Medical receives U.S. FDA approval to start pivotal trial for MINIject in glaucoma patients

Retrieved on: 
Thursday, July 15, 2021
Medicine, Eye surgery, Clinical medicine, Medical specialties, Glaucoma, Cataract surgery, Implant, Minimally invasive glaucoma surgery, Draft:Martin Uram

This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.

Key Points: 
  • This study will report on safety and efficacy of MINIject alone, in a procedure not combined with simultaneous cataract surgery.
  • Patients will also be followed to evaluate long-term benefits and tolerability of MINIjectTM in the treatment of mild to moderate glaucoma.
  • Michel Vanbrabant, CEO of iSTAR Medical, commented "We are very pleased that the FDA has granted us approval to bring this innovative technology to North American patients suffering from primary open angle glaucoma in the STAR-V trial.
  • iSTAR Medical SA is a private med-tech company developing minimally invasive ophthalmic implants for the treatment of glaucoma patients.

Skye Bioscience Expands Clinical Advisory Board with the Appointment of Ophthalmology Expert Dr. Miguel González-Andrades

Retrieved on: 
Thursday, June 10, 2021
Ophthalmology, Health care, Health, Draft:Martin Uram

SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (SKYE or the Company), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advisory Board with the appointment of ophthalmology expert and innovator, Miguel Gonzlez-Andrades, MD, PhD.

Key Points: 
  • SAN DIEGO, CA, June 10, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (SKYE or the Company), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has expanded its Clinical Advisory Board with the appointment of ophthalmology expert and innovator, Miguel Gonzlez-Andrades, MD, PhD.
  • Robert Ritch, MD: Shelley and Steven Einhorn Distinguished Chair in Ophthalmology, Chief of Glaucoma Services and Clinical Professor of Ophthalmology at the Mt.
  • He is a diplomate of the American Board of Ophthalmology and a fellow of the American Academy of Ophthalmology and the Royal College of Ophthalmology.
  • He is a member of multiple editorial boards, including Journal of Glaucoma, American Journal of Ophthalmology, and Ophthalmology Glaucoma.

Glaukos Announces Participation in Oppenheimer Healthcare Conference

Retrieved on: 
Tuesday, March 2, 2021
Pharmaceutical, Optical, Health, Medical devices, Blindness, Glaucoma, Retina, Draft:Martin Uram, Minimally invasive glaucoma surgery

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Oppenheimer 31st Annual Healthcare Conference on Tuesday, March 16, 2021, at 3:10 p.m. EDT.
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.
  • The company pioneered Micro-Invasive Glaucoma Surgery, or MIGS, to revolutionize the traditional glaucoma treatment and management paradigm.
  • Glaukos is leveraging its platform technology to build a comprehensive and proprietary portfolio of micro-scale surgical and pharmaceutical therapies in glaucoma, corneal health and retinal disease.

Glaukos Corporation to Release Fourth Quarter and Full Year 2020 Financial Results after Market Close on February 25

Retrieved on: 
Thursday, February 4, 2021
Medical devices, Health, Surgery, Pharmaceutical, Optical, Biotechnology, Blindness, Glaucoma, Retina, Draft:Martin Uram

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021.

Key Points: 
  • Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release fourth quarter and full year 2020 financial results after the market close on Thursday, February 25, 2021.
  • The companys management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PST (4:30 p.m. EST) on February 25, 2021.
  • A link to the live webcast will be available on the companys website at http://investors.glaukos.com .
  • Glaukos ( www.glaukos.com ) is an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases.